We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Allogene Therapeutics (ALLO) Up 7.4% Since Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for Allogene Therapeutics (ALLO - Free Report) . Shares have added about 7.4% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Allogene Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Allogene’s Q4 Earnings Beat Estimates
Allogene incurred a loss of 54 cents per share for fourth-quarter 2021, narrower than the Zacks Consensus Estimate of a loss of 61 cents but wider than the year-ago loss of 53 cents.
The company recorded revenues of $0.1 million for the quarter. It did not record any revenues in the year-ago quarter.
Quarter in Detail
Research & development (R&D) expenses were $54 million, up 3.4% from the year-ago quarter.
General and administrative (G&A) expenses increased 16.5% year over year to $20 million.
The company had $809.5 million in cash, cash equivalents and investments as of Dec 31, 2021 compared with $861.7 million on Sep 30, 2021.
Full-Year Results
Allogene reported revenues of $38.5 million for 2021. The company did not record any revenues in 2020. In 2021, it incurred a loss of $1.89 per share, narrowing 9.1% from the year-ago period.
2022 Guidance
Allogene issued its guidance for operating expenses for 2021. Operating expenses are expected between $360 million and $390 million.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended upward during the past month.
The consensus estimate has shifted 6.93% due to these changes.
VGM Scores
At this time, Allogene Therapeutics has an average Growth Score of C, though it is lagging a bit on the Momentum Score front with a D. Charting a somewhat similar path, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Allogene Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Allogene Therapeutics (ALLO) Up 7.4% Since Last Earnings Report?
A month has gone by since the last earnings report for Allogene Therapeutics (ALLO - Free Report) . Shares have added about 7.4% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Allogene Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Allogene’s Q4 Earnings Beat Estimates
Allogene incurred a loss of 54 cents per share for fourth-quarter 2021, narrower than the Zacks Consensus Estimate of a loss of 61 cents but wider than the year-ago loss of 53 cents.
The company recorded revenues of $0.1 million for the quarter. It did not record any revenues in the year-ago quarter.
Quarter in Detail
Research & development (R&D) expenses were $54 million, up 3.4% from the year-ago quarter.
General and administrative (G&A) expenses increased 16.5% year over year to $20 million.
The company had $809.5 million in cash, cash equivalents and investments as of Dec 31, 2021 compared with $861.7 million on Sep 30, 2021.
Full-Year Results
Allogene reported revenues of $38.5 million for 2021. The company did not record any revenues in 2020. In 2021, it incurred a loss of $1.89 per share, narrowing 9.1% from the year-ago period.
2022 Guidance
Allogene issued its guidance for operating expenses for 2021. Operating expenses are expected between $360 million and $390 million.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended upward during the past month.
The consensus estimate has shifted 6.93% due to these changes.
VGM Scores
At this time, Allogene Therapeutics has an average Growth Score of C, though it is lagging a bit on the Momentum Score front with a D. Charting a somewhat similar path, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Allogene Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.